Melanoma staging: Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 3, 2010, Pages 275-280

  Forschner, Andrea ^a   Eigentler, Thomas Kurt ^a   Pflugfelder, Annette ^a   Leiter, Ulrike ^a   Weide, Benjamin ^a   Held, Laura ^a   Meier, Friedegund ^a   Garbe, Claus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S 100; TUMOR MARKER;

ARTICLE; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOGRAPHY; FOLLOW UP; HUMAN; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; THICKNESS; BLOOD; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; SECONDARY; SKIN TUMOR; TUMOR RECURRENCE;

DIAGNOSTIC IMAGING; HUMANS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; S100 PROTEINS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953599584     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.06.012     Document Type: Article

References (32)

1. Thompson J.F., Scolyer R.A., Kefford R.F. Cutaneous melanoma. Lancet 2005, 365:687-701.
2. Reintgen D.S. Regional nodal surgery for melanoma impacts recurrence rates and survival. Ann Surg Oncol 2000, 7:80-81.
3. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976-983.
4. Balch C.M., Buzaid A.C., Soong S.J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
5. Miller A.J., Mihm M.C. Melanoma. N Engl J Med 2006, 355:51-65.
6. Wong S.L., Coit D.G. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 2004, 16:155-160.
7. Sharpless S.M., Das Gupta T.K. Surgery for metastatic melanoma. Semin Surg Oncol 1998, 14:311-318.
8. Brand C.U., Ellwanger U., Stroebel W., et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997, 79:2345-2353.
9. Garbe C., Paul A., Kohler-Späth H., et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003, 21:520-529.
10. Bishop J.A.N., Corrie P.G., Evans J., et al. UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 2002, 55:46-54.
11. Terhune M.H., Swanson N., Johnson T.M. Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 1998, 134:569-572.
12. Bafounta M.L., Beauchet A., Chagnon S., Saiag P. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol 2004, 5:673-680.
13. Blum A., Schlagenhauff B., Stroebel W., Breuninger H., Rassner G., Garbe C. Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. Cancer 2000, 88:2534-2539.
14. Garbe C., Leiter U. In reply: Prospective evaluation of a follow-up schedule in 2,008 patients with cutaneous melanoma: recommendations for an effective follow-up strategy. J Clin Oncol 2003, 21:3706-3707.
15. Kaufmann P.M., Crone-Münzebrock W. Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma. Aktuelle Radiol 1992, 2:81-85.
16. Fink A.M., Holle-Robatsch S., Herzog N., et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004, 14:141-145.
17. Singh B., Ezziddin S., Palmedo H., et al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res 2008, 18:346-352.
18. Kell M.R., Ridge J.A., Joseph N., Sigurdson E.R. PET CT imaging in patients undergoing sentinel node biopsy for melanoma. Eur J Surg Oncol 2007, 33:911-913.
19. Aloia T.A., Gershenwald J.E., Andtbacka R.H., et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006, 24:2858-2865.
20. Constantinidou A., Hofman M., O'Doherty M., Acland K.M., Healy C., Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res 2008, 18:56-60.
21. Horn J., Lock-Andersen J., Sjøstrand H., Loft A. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2006, 33:887-892.
22. Abraha H.D., Fuller L.C., Du Vivier A.W., Higgins E.M., Sherwood R.A. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997, 137:381-385.
23. Andrés R., Mayordomo J.I., Zaballos P., et al. Prognostic value of serum S-100B in malignant melanoma. Tumori 2004, 90:607-610.
24. Garbe C., Schadendorf D. Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 2003, 26:241-246.
25. Strobel K., Skalsky J., Kalff V., et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging 2007, 34:1366-1375.
26. Reinhardt M.J., Joe A.Y., Jaeger U., et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006, 24:1178-1187.
27. Fuster D., Chiang S., Johnson G., Schuchter L.M., Zhuang H., Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?. J Nucl Med 2004, 45:1323-1327.
28. Reinhardt M.J., Kensy J., Frohmann J.P., et al. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data. Nuklearmedizin 2002, 41:143-147.
29. Wagner J.D., Schauwecker D., Davidson D., et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005, 104:570-579.
30. Strobel K., Dummer R., Husarik D.B., Pérez Lago M., Hany T.F., Steinert H.C. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007, 244:566-574.
31. Rinne D., Baum R.P., Hör G., Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998, 82:1664-1671.
32. Müller-Horvat C., Radny P., Eigentler T.K., et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 2006, 42:342-350.